Renal cell carcinoma: Therapy change can significantly improve treatment result

A research team was able to demonstrate that a therapy change in the area of metastasizing renal cell carcinoma significantly increases the life average expectancy and clearly improves the compatibility of the therapy. The extent of the influence of the administration rhythm of Sunitinib, an effective ingredient which is utilised in the target-oriented therapy, on the treatment results was examined. The result: In 71% of the patients, the therapy change resulted in an average survival extension of 33 months to approximately 75 months. (Mehr in: Cancer News — ScienceDaily)